PPI - Radically Pragmatic
  • Donate
Skip to content
  • Home
  • About
    • About Us
    • Locations
    • Careers
  • People
  • Projects
  • Our Work
  • Events
  • Donate

Our Work

New PPI analysis makes case for why the Biden administration should revisit FTC merger policy to promote competition in pharmaceuticals

  • October 24, 2023
  • Diana Moss

Data shows that American consumers pay more for prescription drugs than in any other country, and in 2021, the Biden administration’s landmark Executive Order (EO) included a focus on promoting competition in the pharmaceutical industry. While the EO outlined a comprehensive approach to promoting competition and controlling drug prices, the administration left out one critical tool in their toolkit — the FTC’s merger control policy.

Today, the Progressive Policy Institute (PPI) released an analysis suggesting that the administration’s executive order has not fully delivered on the promise of promoting competition in the pharmaceutical sector. The analysis, “Promoting Competition in Pharmaceutical Markets: Is the Biden Executive Order Delivering on the Promise?” focuses on the FTC’s longstanding, controversial pharmaceutical merger policy. It calls out the administration for missing an important opportunity to revisit the FTC’s policy to better promote pharmaceutical competition and bring down prescription drug prices for everyday consumers.

“The Biden administration should deliver on its promise to use a ‘whole-of-government’ approach to promoting competition in the pharma sector,” said report author Diana Moss, Vice President and Director of Competition Policy at PPI. “That means looking to merger control by the FTC as a major tool for preventing harmful consolidation and protecting consumers. But it also means reforming the FTC’s approach to pharma mergers, which has fostered rising concentration in critical drug markets.”

Read and download the full response to the Executive Order here.

The Progressive Policy Institute (PPI) is a catalyst for policy innovation and political reform based in Washington, D.C., with offices in Brussels, Berlin and the United Kingdom. Its mission is to create radically pragmatic ideas for moving America beyond ideological and partisan deadlock. Learn more about PPI by visiting progressivepolicy.org.

Follow the Progressive Policy Institute.

Find an expert at PPI.

###

Media Contact: Amelia Fox, afox@ppionline.org

Related Work

Blog  |  December 16, 2025

The Demise of iRobot: How Antitrust Enforcers Missed the Elephant in the Room

  • Diana Moss
Op-Ed  |  December 11, 2025

Moss for Promarket: Canceling the Antitrust Show? Live Nation-Ticketmaster’s Latest Attempt To Keep Its Monopoly

  • Diana Moss
In the News  |  December 8, 2025

Moss in The Washington Post: Netflix to buy Warner Bros. Discovery in $83 billion deal

  • Diana Moss
In the News  |  December 8, 2025

Moss in Time Magazine: How Trump Could Kill the Netflix-Warner Bros. Deal

  • Diana Moss
Press Release  |  December 2, 2025

PPI Warns That Hospital Takeovers of Physician Practices Are Driving Up Costs and Reducing Patient Access

  • Diana Moss Alix Ware Lief Lin
Publication  |  December 2, 2025

Fixing a Broken System: Policy Responses to Hospital Acquisitions of Physician Practices That Limit Health Care Access for U.S. Consumers

  • Diana Moss Alix Ware Lief Lin
  • Never miss an update:

  • Subscribe to our newsletter
PPI Logo
  • Twitter
  • LinkedIn
  • Facebook
  • Donate
  • Careers
  • © 2025 Progressive Policy Institute. All Rights Reserved.
  • |
  • Privacy Policy
  • |
  • Privacy Settings